Gyre Therapeutics (GYRE) Equity Average (2016 - 2025)
Historic Equity Average for Gyre Therapeutics (GYRE) over the last 15 years, with Q3 2025 value amounting to $133.4 million.
- Gyre Therapeutics' Equity Average rose 3911.9% to $133.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $133.4 million, marking a year-over-year increase of 3911.9%. This contributed to the annual value of $41.3 million for FY2024, which is 4643.64% up from last year.
- Latest data reveals that Gyre Therapeutics reported Equity Average of $133.4 million as of Q3 2025, which was up 3911.9% from $116.9 million recorded in Q2 2025.
- In the past 5 years, Gyre Therapeutics' Equity Average registered a high of $133.4 million during Q3 2025, and its lowest value of -$27.1 million during Q2 2023.
- In the last 5 years, Gyre Therapeutics' Equity Average had a median value of $54.2 million in 2022 and averaged $60.6 million.
- In the last 5 years, Gyre Therapeutics' Equity Average plummeted by 15112.49% in 2023 and then surged by 169918.77% in 2024.
- Over the past 5 years, Gyre Therapeutics' Equity Average (Quarter) stood at $50.9 million in 2021, then fell by 0.23% to $50.8 million in 2022, then plummeted by 112.12% to -$6.2 million in 2023, then soared by 1699.19% to $98.4 million in 2024, then skyrocketed by 35.55% to $133.4 million in 2025.
- Its last three reported values are $133.4 million in Q3 2025, $116.9 million for Q2 2025, and $101.4 million during Q1 2025.